RxDoctor Payments Data

Kenza Pokrywa, PA

Physician Assistant · Louisville, KYNPI 1467166785

Payments from drug & device makers

$3,031in general payments, 2019–2025

Across 109 payments — averaging $27.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$562
  • Novo Nordisk$354
  • GSK$202
  • Astellas Pharma US Inc$141
  • Amgen$138
  • plus $591 from 11 others

What the payments were for

  • Food & beverage$3,031100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,031 in reported general payments places this provider in the 85th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$16,349
Medicare patients
97
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$27,273
OzempicSemaglutide12$10,114
Repatha SureclickEvolocumab16$9,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,216
Albuterol Sulfate HfaAlbuterol Sulfate34$691
Pantoprazole Sodium20$287
Amlodipine Besylate37$277
Rosuvastatin Calcium51$262
Metoprolol Succinate19$185
Levothyroxine Sodium33$154
Atorvastatin Calcium32$133
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide12$116
Tizanidine Hcl15$49
Tamsulosin Hcl13$42
Ezetimibe11$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$80$27,27328 claims
Novo NordiskOzempic$354$10,11412 claims
GSKTrelegy Ellipta$202$8,21613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →